Cantor upgrades Capricor to Overweight, lifts target to $28
Cantor Fitzgerald upgrades Capricor Therapeutics to Overweight from Neutral and raises its price target to $28 from $3.50 after the Q2 call centered on the negative FDA panel vote for deramiocel.